MoonLake Immunotherapeutics, (MLTX): Price and Financial Metrics


MoonLake Immunotherapeutics, (MLTX): $9.33

-0.74 (-7.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MLTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MLTX Stock Price Chart Interactive Chart >

Price chart for MLTX

MLTX Price/Volume Stats

Current price $9.33 52-week high $15.19
Prev. close $10.07 52-week low $4.25
Day low $9.17 Volume 28,800
Day high $9.56 Avg. volume 87,472
50-day MA $8.52 Dividend yield N/A
200-day MA $7.60 Market Cap 491.70M

MoonLake Immunotherapeutics, (MLTX) Company Bio


MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.


MLTX Latest News Stream


Event/Time News Detail
Loading, please wait...

MLTX Latest Social Stream


Loading social stream, please wait...

View Full MLTX Social Stream

Latest MLTX News From Around the Web

Below are the latest news stories about MOONLAKE IMMUNOTHERAPEUTICS that investors may wish to consider to help them evaluate MLTX as an investment opportunity.

MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update

MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update Global trial of sonelokimab in Hidradenitis Suppurativa (HS) has continued to meet recruitment targets with an expected primary endpoint readout in mid-2023Global Psoriatic Arthritis (PsA) trial received FDA clearance and US central IRB approvalQuarter-end position of $83.5 million in cash, cash equivalents and short-term marketable debt securities, providing cash runway into 2H2024 and a

Yahoo | November 14, 2022

Analysts Are Bullish on Top Healthcare Stocks: First Wave Bio (FWBI), Atara Biotherapeutics (ATRA)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on First Wave Bio (FWBI – Research Report), Atara Biotherapeutics (ATRA – Research Report) and MoonLake Immunotherapeutics (MLTX – Research Report) with bullish sentiments. First Wave Bio (FWBI) In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on First Wave Bio, with a price target of $8.00. The company's shares closed last Friday at $1.13, close to its 52-week low of $1.06. According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of -30.8% and a 21.5% success rate.

Howard Kim on TipRanks | October 31, 2022

FDA Clears MoonLake's Nanobody Study For Arthritis Patients

The FDA has signed off MoonLake Immunotherapeutics AG's (NASDAQ: MLTX) Phase 2 study of the nanobody sonelokimab in patients with active psoriatic arthritis (PsA). This is a global clinical study that also includes several European countries. This new study is subsequent to the completion of a global Phase 2b study in moderate-to-severe psoriasis and the initiation of Phase 2 MIRA study in moderate-to-severe hidradenitis suppurativa. Related: HC Wainwright Starts Coverage On This 'Best-In-Class

Yahoo | September 26, 2022

MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis

MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis MoonLake announces FDA clearance for Phase 2 clinical study of the Nanobody® sonelokimab in active psoriatic arthritisExpected to enroll approximately 200 patients to assess the efficacy and safety of sonelokimab compared to placebo, with adalimumab as an active reference arm; recruitment expected to commence shortly in the United States and EuropeThis Phase 2 stu

Yahoo | September 26, 2022

Got a Buy List Ready? Analysts Think These 2 “Strong Buy” Stocks Should Be On It

The truth will set you free? Perhaps – or perhaps it will disillusion you. In late August, Federal Reserve Chair Jerome Powell issued a hawkish update at the Jackson Hole Symposium. Powell was brutally honest on the subject of inflation, more so than anyone had thought he would be beforehand. Powell said, simply, that neither inflation nor higher interest rates are going away any time soon. The markets did what they are wont to do when faced with unwelcome news – they crashed across the board. However, that drop opens up the opportunity for investors willing to do a bit of bottom fishing.

Michael Marcus on TipRanks | September 8, 2022

Read More 'MLTX' Stories Here

MLTX Price Returns

1-mo 19.46%
3-mo 19.16%
6-mo 80.46%
1-year -6.04%
3-year N/A
5-year N/A
YTD -5.66%
2021 -13.02%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5345 seconds.